Results 101 to 110 of about 121,016 (287)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Leukemia Research Reports, 2018
Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19.
Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Salman   +7 more
doaj   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Strength of T cell signaling regulates HIV-1 replication and establishment of latency.

PLoS Pathogens, 2019
A major barrier to curing HIV-1 is the long-lived latent reservoir that supports re-emergence of HIV-1 upon treatment interruption. Targeting this reservoir will require mechanistic insights into the establishment and maintenance of HIV-1 latency ...
Matthew Gagne, Daniel Michaels, Gillian M Schiralli Lester, Suryaram Gummuluru, Wilson W Wong, Andrew J Henderson   +5 more
doaj   +1 more source

Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM [PDF]

, 2007
The continuously growing natural killer (NK) cell line NK-92 is highly cytotoxic against malignant cells of various origin without affecting normal human cells.
Klingemann, Hans-Georg, Müller, Tina, Tonn, Torsten, Uherek, Barbara, Uherek, Christoph, Wels, Winfried S.   +5 more
core  

New simplified molecular design for functional T cell receptor [PDF]

, 1993
We have produced a chimeric single-chain T cell receptor (TcR) that combines the specific antibody recognition function and TcR/CD3 signaling properties within the same polypeptide chain.
Clevers, Cosson, Eshhar, Frank, Gillis, Gunning, Hackett, Huston, Ihle, Irving, Lanzavecchia, Leo, Mosmann, Oi, Romeo, Sterz, Tada, Traunecker, Walker, Wegener, Weissman, Weissman, White, Zamoyska   +23 more
core   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Developing T-cell therapies for lymphoma without receptor engineering

Blood Advances, 2017
: T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient's immune system status and disease stage.
Melanie Grant, Catherine M. Bollard
doaj   +1 more source

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. [PDF]

, 2015
Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to control. Despite some benefit from using the multimodality-approach (surgery, combination chemotherapy and radiation), survival remains poor. However, current research produced a
Cameron, Robert B, Kotova, Svetlana, Wong, Raymond M   +2 more
core   +2 more sources

DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss

Advanced Science, EarlyView.
Senescent bone marrow stromal cells accumulate in the aging bone microenvironment, promoting bone degeneration. DEL‐1, an endogenous secreted protein, acts as a natural senolytic that selectively eliminates these cells. By engaging a β3 integrin/CD73/adenosine/p38 MAPK/BCL‐2 pathway, DEL‐1 counters aging‐related bone loss, revealing promising ...
Jong‐Hyung Lim, Kridtapat Sirisereephap, Hui Wang, Giulia Trimaglio, Kyoung‐Jin Chung, Jonathan Korostoff, Tetsuhiro Kajikawa, Xiaofei Li, Meircurius D.C. Surboyo, Tomoki Maekawa, Triantafyllos Chavakis, George Hajishengallis   +11 more
wiley   +1 more source

Utilizing chimeric antigen receptors to direct natural killer cell activity

Frontiers in Immunology, 2015
Natural killer (NK) cells represent an attractive lymphocyte population for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization and without need for HLA-matching.
Dan S Kaufman, David eHermanson
doaj   +1 more source